Detalhe da pesquisa
1.
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Cell
; 173(6): 1413-1425.e14, 2018 05 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29754815
2.
Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation.
Cell
; 156(5): 986-1001, 2014 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-24581497
3.
Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis.
Cell
; 151(5): 1068-82, 2012 Nov 21.
Artigo
Inglês
| MEDLINE | ID: mdl-23142051
4.
Muscleblind-like 1 suppresses breast cancer metastatic colonization and stabilizes metastasis suppressor transcripts.
Genes Dev
; 30(4): 386-98, 2016 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26883358
5.
Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma.
Int J Mol Sci
; 23(14)2022 Jul 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35886842
6.
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Cancer Res
; 81(7): 1775-1787, 2021 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33531370
7.
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
JCI Insight
; 4(21)2019 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31600169
8.
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
Nat Med
; 24(2): 203-212, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29334371
9.
Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.
Cell Rep
; 20(1): 48-60, 2017 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28683323
10.
Control of metastatic progression by microRNA regulatory networks.
Nat Cell Biol
; 15(6): 546-54, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23728460